Milestone Pharmaceuticals Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | $559.00K | $-0.21 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | $200.00K | $-0.20 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 20, 2026 | Before market open | $1.50M | $-0.16 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | Before market open | – | $-0.19 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | $-0.14 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | $-0.21 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | Before market open | – | – | – |
Press releases
Announcements Milestone Pharmaceuticals filed with the SEC
Milestone Pharmaceuticals Announces NMPA Approval
Other events · EX-99.1 to Form 8-K
Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Milestone Pharmaceuticals Announces First Quarter
Results of operations · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil)
Results of operations · EX-99.1 to Form 8-K
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™
Other events · EX-99.1 to Form 8-K
of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
Other events · EX-99.1 to Form 8-K
FDA Approval Investor Call December 15, 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Milestone Receives FDA Approval of CARDAMYST™
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Results of operations · EX-99.1 to Form 8-K
MONTREAL, Quebec and CHARLOTTE, N.C., July 11,
Material agreement · Other events · EX-99.1 to Form 8-K
of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
Material agreement · Other events · EX-99.2 to Form 8-K
Milestone Pharmaceuticals Announces FDA Acceptance
Material agreement · Other events · EX-99.1 to Form 8-K
Milestone Pharmaceuticals Submits Response to
Other events · EX-99.1 to Form 8-K
Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Results of operations · EX-99.1 to Form 8-K
FDA Issues Complete Response Letter for Etripamil
Other events · EX-99.1 to Form 8-K
Milestone Pharmaceuticals Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Joe Oliveto, President & CEO
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and
Results of operations · EX-99.1 to Form 8-K
Veteran Joseph Papa to its Board of Directors
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Milestone Pharmaceuticals Refreshes Board of Directors
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
Announces FDA Acceptance of New Drug Application for CARDAMYST™
Other events · EX-99.1 to Form 8-K
Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American
Other events · EX-99.1 to Form 8-K
Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
Other events · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Public Offering of Common Shares and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants
Material agreement · Other events · EX-99.2 to Form 8-K
Milestone Pharmaceuticals Announces Plan to
Other events · EX-99.1 to Form 8-K
Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT
Other events · EX-99.1 to Form 8-K
Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Company Overview CONFIDENTIAL Atrial Fibrillation Program Update November 2023
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Milestone Pharmaceuticals to Host Investor and
Regulation FD disclosure · EX-99.1 to Form 8-K
of New Drug Application to the U.S. FDA for Etripamil
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Company Overview March 30, 2023
New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update
Results of operations · EX-99.1 to Form 8-K